Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells $49,511.00 in Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 1,100 shares of the company’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $45.01, for a total value of $49,511.00. Following the completion of the transaction, the director now owns 318,652 shares of the company’s stock, valued at approximately $14,342,526.52. This represents a 0.34 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Pro-Dex Stock Performance

PDEX traded down $2.76 during trading hours on Monday, hitting $35.22. 5,716 shares of the stock were exchanged, compared to its average volume of 30,806. The stock has a 50-day simple moving average of $47.43 and a 200-day simple moving average of $34.74. Pro-Dex, Inc. has a 12 month low of $16.18 and a 12 month high of $59.60. The stock has a market cap of $114.80 million, a price-to-earnings ratio of 17.73 and a beta of 0.53. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.58 and a quick ratio of 1.44.

Pro-Dex (NASDAQ:PDEX) last announced its quarterly earnings data on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.23. Pro-Dex had a return on equity of 21.68% and a net margin of 11.06%. Analysts anticipate that Pro-Dex, Inc. will post 2 earnings per share for the current year.

Analyst Upgrades and Downgrades

PDEX has been the subject of several research analyst reports. Ascendiant Capital Markets increased their target price on Pro-Dex from $30.00 to $52.00 and gave the company a “buy” rating in a research note on Monday, November 11th. StockNews.com upgraded Pro-Dex from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 14th.

Hedge Funds Weigh In On Pro-Dex

Several large investors have recently added to or reduced their stakes in PDEX. Ritholtz Wealth Management acquired a new stake in Pro-Dex in the fourth quarter worth $572,000. JPMorgan Chase & Co. increased its position in Pro-Dex by 2.2% in the third quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock worth $740,000 after buying an additional 529 shares during the period. Geode Capital Management LLC increased its position in Pro-Dex by 9.1% in the third quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock worth $819,000 after buying an additional 2,296 shares during the period. FMR LLC increased its position in Pro-Dex by 34.9% in the third quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock worth $119,000 after buying an additional 1,028 shares during the period. Finally, Bard Associates Inc. increased its position in Pro-Dex by 17.6% in the third quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock worth $406,000 after buying an additional 2,031 shares during the period. 15.28% of the stock is currently owned by institutional investors.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.